Clinical Trial Detail

NCT ID NCT04238819
Title A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

central nervous system cancer

Advanced Solid Tumor

Therapies

Abemaciclib + Temozolomide

Abemaciclib + Irinotecan + Temozolomide

Age Groups: adult child

No variant requirements are available.